Skadden advised Everest Medicines, a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, in its placing of existing shares and top-up subscription of new shares under general mandate, raising HK$1,572.50 million (US$200 million). The transaction was completed on August 1, 2025.
Further details about the transaction can be found here.
The Skadden team was led by partner and China practice co-head Paloma Wang, supported by counsel Martina To and associate Adriana Chiuin Hong Kong.
